Zimbru Elena-Larisa, Zimbru Răzvan-Ionuț, Ordodi Valentin-Laurențiu, Bojin Florina-Maria, Crîsnic Daniela, Andor Minodora, Mirica Silvia-Nicoleta, Huțu Ioan, Tănasie Gabriela, Haidar Laura, Nistor Daciana, Velcean Luminița, Păunescu Virgil, Panaitescu Carmen
Center of Immuno-Physiology and Biotechnologies, Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Research Center for Gene and Cellular Therapies in the Treatment of Cancer-OncoGen, Timis County Emergency Clinical Hospital "Pius Brinzeu", No. 156 Liviu Rebreanu, 300723 Timisoara, Romania.
Nutrients. 2024 Nov 28;16(23):4104. doi: 10.3390/nu16234104.
A growing body of evidence links a high-fructose diet (HFrD) to metabolic disturbances, including inflammation, dyslipidemia, insulin resistance and also endothelial dysfunction, yet its role in allergic asthma remains underexplored. Considering that obesity and hypercholesterolemia exacerbate asthma by promoting systemic inflammation, investigating interventions with dual metabolic and anti-inflammatory effects is essential. This study aimed to evaluate the potential modulatory effects of rosuvastatin in ameliorating the effects of HFrD-induced metabolic and vascular dysfunction in the context of allergic asthma.
Forty-eight Sprague-Dawley rats were assigned to eight groups, receiving either a standard or HFrD for 12 weeks. Allergic asthma was induced using an ovalbumin sensitization and challenge protocol, while controls were administered saline. Selected groups were treated with rosuvastatin throughout the entire duration of the experiment. Body weight, abdominal circumference and serum biomarkers were assessed at baseline, 6 and 12 weeks. Endothelial function was assessed by evaluating vascular reactivity in an isolated organ bath. Additionally, histopathological analyses of aortic and pulmonary tissues were conducted to investigate inflammatory responses and morphological changes.
Rats on HFrDs exhibited significant increases in body weight, abdominal circumference, lipid profiles and blood glucose, which were further aggravated by allergic asthma. Rosuvastatin treatment notably reduced lipid levels, C-reactive protein and immunoglobulin E, while also enhancing vascular reactivity and attenuating aortic and bronchial wall thickening.
Our findings suggest that rosuvastatin may serve as an effective therapeutic agent for addressing vascular and inflammatory complications associated with a high fructose intake and allergic asthma.
越来越多的证据表明，高果糖饮食（HFrD）与代谢紊乱有关，包括炎症、血脂异常、胰岛素抵抗以及内皮功能障碍，但其在过敏性哮喘中的作用仍未得到充分研究。鉴于肥胖和高胆固醇血症通过促进全身炎症而加重哮喘，研究具有双重代谢和抗炎作用的干预措施至关重要。本研究旨在评估瑞舒伐他汀在改善过敏性哮喘背景下HFrD诱导的代谢和血管功能障碍方面的潜在调节作用。
将48只Sprague-Dawley大鼠分为8组，分别给予标准饮食或HFrD 12周。使用卵清蛋白致敏和激发方案诱导过敏性哮喘，对照组给予生理盐水。选定的组在整个实验过程中用瑞舒伐他汀治疗。在基线、6周和12周时评估体重、腹围和血清生物标志物。通过评估离体器官浴中的血管反应性来评估内皮功能。此外，对主动脉和肺组织进行组织病理学分析，以研究炎症反应和形态学变化。
食用HFrD的大鼠体重、腹围、血脂和血糖显著增加，过敏性哮喘使其进一步加重。瑞舒伐他汀治疗显著降低了血脂水平、C反应蛋白和免疫球蛋白E，同时还增强了血管反应性，减轻了主动脉和支气管壁增厚。
我们的研究结果表明，瑞舒伐他汀可能是一种有效的治疗药物，用于解决与高果糖摄入和过敏性哮喘相关的血管和炎症并发症。
